Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

S. Ravassa; B. Lopez; J.P. Ferreira; N. Girerd; E. Bozec; P. Pellicori; B. Mariottoni; F. Cosmi; M. Hazebroek; J.A.J. Verdonschot; J. Cuthbert; J. Petutschnigg; M.U. Moreno; S. Heymans; J.A. Staessen; B. Pieske; F. Edelmann; A.L. Clark; J.G.F. Cleland; F. Zannad; J. Diez; A. Gonzalez; HOMAGE Trial Committees and Investigators

doi:10.1002/ejhf.2394

Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

S. Ravassa, B. Lopez, J.P. Ferreira, N. Girerd, E. Bozec, P. Pellicori, B. Mariottoni, F. Cosmi, M. Hazebroek, J.A.J. Verdonschot, J. Cuthbert, J. Petutschnigg, M.U. Moreno, S. Heymans, J.A. Staessen, B. Pieske, F. Edelmann, A.L. Clark, J.G.F. Cleland, F. ZannadJ. Diez^*, A. Gonzalez^*, HOMAGE Trial Committees and Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	321-331
Number of pages	11
Journal	European journal of heart failure
Volume	24
Issue number	2
Early online date	9 Dec 2021
DOIs	https://doi.org/10.1002/ejhf.2394
Publication status	Published - Feb 2022

Keywords

Heart failure
Spironolactone
Atrial remodelling
Collagen cross-linking
PRESERVED EJECTION FRACTION
MAGNETIC-RESONANCE
EXERCISE CAPACITY
VOLUME
FIBROSIS
FIBRILLATION
DYSFUNCTION
SURVIVAL

Access to Document

10.1002/ejhf.2394Licence: CC BY-NC-ND

Cite this

Ravassa, S., Lopez, B., Ferreira, J. P., Girerd, N., Bozec, E., Pellicori, P., Mariottoni, B., Cosmi, F., Hazebroek, M., Verdonschot, J. A. J., Cuthbert, J., Petutschnigg, J., Moreno, M. U., Heymans, S., Staessen, J. A., Pieske, B., Edelmann, F., Clark, A. L., Cleland, J. G. F., ... HOMAGE Trial Committees and Investigators (2022). Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. European journal of heart failure, 24(2), 321-331. https://doi.org/10.1002/ejhf.2394

Ravassa, S. ; Lopez, B. ; Ferreira, J.P. ; Girerd, N. ; Bozec, E. ; Pellicori, P. ; Mariottoni, B. ; Cosmi, F. ; Hazebroek, M. ; Verdonschot, J.A.J. ; Cuthbert, J. ; Petutschnigg, J. ; Moreno, M.U. ; Heymans, S. ; Staessen, J.A. ; Pieske, B. ; Edelmann, F. ; Clark, A.L. ; Cleland, J.G.F. ; Zannad, F. ; Diez, J. ; Gonzalez, A. ; HOMAGE Trial Committees and Investigators. / Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. In: European journal of heart failure. 2022 ; Vol. 24, No. 2. pp. 321-331.

@article{ea6ff60915e7436b85accd35632f8264,

title = "Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial",

keywords = "Heart failure, Spironolactone, Atrial remodelling, Collagen cross-linking, PRESERVED EJECTION FRACTION, MAGNETIC-RESONANCE, EXERCISE CAPACITY, VOLUME, FIBROSIS, FIBRILLATION, DYSFUNCTION, SURVIVAL",

author = "S. Ravassa and B. Lopez and J.P. Ferreira and N. Girerd and E. Bozec and P. Pellicori and B. Mariottoni and F. Cosmi and M. Hazebroek and J.A.J. Verdonschot and J. Cuthbert and J. Petutschnigg and M.U. Moreno and S. Heymans and J.A. Staessen and B. Pieske and F. Edelmann and A.L. Clark and J.G.F. Cleland and F. Zannad and J. Diez and A. Gonzalez and {HOMAGE Trial Committees and Investigators}",

year = "2022",

month = feb,

doi = "10.1002/ejhf.2394",

language = "English",

volume = "24",

pages = "321--331",

journal = "European journal of heart failure",

issn = "1388-9842",

publisher = "Wiley",

number = "2",

}

Ravassa, S, Lopez, B, Ferreira, JP, Girerd, N, Bozec, E, Pellicori, P, Mariottoni, B, Cosmi, F, Hazebroek, M, Verdonschot, JAJ, Cuthbert, J, Petutschnigg, J, Moreno, MU, Heymans, S, Staessen, JA, Pieske, B, Edelmann, F, Clark, AL, Cleland, JGF, Zannad, F, Diez, J, Gonzalez, A & HOMAGE Trial Committees and Investigators 2022, 'Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial', European journal of heart failure, vol. 24, no. 2, pp. 321-331. https://doi.org/10.1002/ejhf.2394

Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. / Ravassa, S.; Lopez, B.; Ferreira, J.P.; Girerd, N.; Bozec, E.; Pellicori, P.; Mariottoni, B.; Cosmi, F.; Hazebroek, M.; Verdonschot, J.A.J.; Cuthbert, J.; Petutschnigg, J.; Moreno, M.U.; Heymans, S.; Staessen, J.A.; Pieske, B.; Edelmann, F.; Clark, A.L.; Cleland, J.G.F.; Zannad, F.; Diez, J.; Gonzalez, A.; HOMAGE Trial Committees and Investigators.

In: European journal of heart failure, Vol. 24, No. 2, 02.2022, p. 321-331.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

AU - Ravassa, S.

AU - Lopez, B.

AU - Ferreira, J.P.

AU - Girerd, N.

AU - Bozec, E.

AU - Pellicori, P.

AU - Mariottoni, B.

AU - Cosmi, F.

AU - Hazebroek, M.

AU - Verdonschot, J.A.J.

AU - Cuthbert, J.

AU - Petutschnigg, J.

AU - Moreno, M.U.

AU - Heymans, S.

AU - Staessen, J.A.

AU - Pieske, B.

AU - Edelmann, F.

AU - Clark, A.L.

AU - Cleland, J.G.F.

AU - Zannad, F.

AU - Diez, J.

AU - Gonzalez, A.

AU - HOMAGE Trial Committees and Investigators

PY - 2022/2

Y1 - 2022/2

KW - Heart failure

KW - Spironolactone

KW - Atrial remodelling

KW - Collagen cross-linking

KW - PRESERVED EJECTION FRACTION

KW - MAGNETIC-RESONANCE

KW - EXERCISE CAPACITY

KW - VOLUME

KW - FIBROSIS

KW - FIBRILLATION

KW - DYSFUNCTION

KW - SURVIVAL

U2 - 10.1002/ejhf.2394

DO - 10.1002/ejhf.2394

M3 - Article

C2 - 34841615

VL - 24

SP - 321

EP - 331

JO - European journal of heart failure

JF - European journal of heart failure

SN - 1388-9842

IS - 2

ER -

Ravassa S, Lopez B, Ferreira JP, Girerd N, Bozec E, Pellicori P et al. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. European journal of heart failure. 2022 Feb;24(2):321-331. https://doi.org/10.1002/ejhf.2394